Adult Congenital Heart Disease International EValuation of the Effectiveness of SGLT2i Registry
Launched by LEIDEN UNIVERSITY MEDICAL CENTER · Apr 9, 2025
Trial Information
Current as of June 26, 2025
Recruiting
Keywords
ClinConnect Summary
The Adult Congenital Heart Disease International Registry is a study looking at how effective a type of medication called sodium-glucose cotransporter 2 inhibitors (SGLT2i) is for adults with congenital heart disease. This registry aims to understand how often these medications are prescribed, how safe they are, and whether they help improve heart failure symptoms in individuals with conditions like transposition of the great arteries, Fontan, or tetralogy of Fallot, among others.
To participate in this study, you need to be at least 18 years old and have a congenital heart defect. You must also be starting treatment with an SGLT2i. If you decide to join, you'll be helping researchers gather important information about the experiences of patients like you. Your participation will involve sharing some health information, but your consent is essential for that. This study is actively recruiting participants, and everyone, regardless of gender, is welcome to take part.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Congenital heart defect.
- • Age ≥ 18 years.
- • Initiated on treatment with an SGLT2i.
- Exclusion Criteria:
- • - No consent for data collection.
About Leiden University Medical Center
Leiden University Medical Center (LUMC) is a prominent academic medical center located in the Netherlands, renowned for its commitment to advancing healthcare through innovative research and high-quality patient care. As a clinical trial sponsor, LUMC focuses on translating scientific discoveries into effective therapies, fostering collaborations between researchers, clinicians, and industry partners. The center is dedicated to conducting rigorous clinical studies across various medical fields, ensuring adherence to ethical standards and regulatory requirements while prioritizing patient safety and outcomes. Through its multidisciplinary approach, LUMC aims to contribute significantly to the understanding and treatment of complex health conditions, driving progress in personalized medicine and improving global health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Baltimore, Maryland, United States
Cardiff, , United Kingdom
Utrecht, , Netherlands
Grand Rapids, Michigan, United States
London, , United Kingdom
Leiden, Zuid Holland, Netherlands
Amsterdam, , Netherlands
New York City, New York, United States
Skopje, , Macedonia, The Former Yugoslav Republic Of
Glasgow, , United Kingdom
Skopje, , North Macedonia
Patients applied
Trial Officials
Anastasia D. Egorova, MD PhD
Principal Investigator
Leiden University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported